Inspire Investing LLC Sells 2,692 Shares of BioCryst Pharmaceuticals, Inc. $BCRX

Inspire Investing LLC reduced its position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 5.9% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 43,209 shares of the biotechnology company’s stock after selling 2,692 shares during the period. Inspire Investing LLC’s holdings in BioCryst Pharmaceuticals were worth $387,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in BCRX. Assenagon Asset Management S.A. grew its holdings in BioCryst Pharmaceuticals by 25,631.2% during the 2nd quarter. Assenagon Asset Management S.A. now owns 3,620,637 shares of the biotechnology company’s stock valued at $32,441,000 after buying an additional 3,606,566 shares in the last quarter. Doliver Advisors LP grew its holdings in BioCryst Pharmaceuticals by 269.1% during the 2nd quarter. Doliver Advisors LP now owns 274,328 shares of the biotechnology company’s stock valued at $2,458,000 after buying an additional 200,000 shares in the last quarter. Acadian Asset Management LLC grew its holdings in BioCryst Pharmaceuticals by 244.1% during the 1st quarter. Acadian Asset Management LLC now owns 670,361 shares of the biotechnology company’s stock valued at $5,023,000 after buying an additional 475,564 shares in the last quarter. Millennium Management LLC grew its holdings in BioCryst Pharmaceuticals by 382.6% during the 1st quarter. Millennium Management LLC now owns 3,812,874 shares of the biotechnology company’s stock valued at $28,597,000 after buying an additional 3,022,769 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC purchased a new position in BioCryst Pharmaceuticals during the 1st quarter valued at approximately $79,000. 85.88% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several equities analysts have weighed in on BCRX shares. Royal Bank Of Canada restated an “outperform” rating and set a $13.00 price target on shares of BioCryst Pharmaceuticals in a report on Monday, June 30th. Evercore ISI reissued an “in-line” rating and set a $8.00 price target on shares of BioCryst Pharmaceuticals in a research note on Wednesday, October 1st. Bank of America raised their price objective on BioCryst Pharmaceuticals from $13.00 to $15.00 and gave the stock a “buy” rating in a report on Tuesday, July 1st. TD Cowen began coverage on BioCryst Pharmaceuticals in a report on Wednesday. They set a “buy” rating and a $30.00 price objective on the stock. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of BioCryst Pharmaceuticals in a report on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $19.18.

BioCryst Pharmaceuticals Price Performance

BioCryst Pharmaceuticals stock opened at $6.72 on Friday. The business has a fifty day moving average price of $7.87 and a 200-day moving average price of $8.64. BioCryst Pharmaceuticals, Inc. has a 1-year low of $6.00 and a 1-year high of $11.31. The stock has a market capitalization of $1.41 billion, a price-to-earnings ratio of -37.33, a PEG ratio of 1.43 and a beta of 1.05.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its quarterly earnings results on Monday, August 4th. The biotechnology company reported $0.15 EPS for the quarter, topping analysts’ consensus estimates of $0.03 by $0.12. The firm had revenue of $163.35 million for the quarter, compared to analyst estimates of $149.59 million. During the same period in the prior year, the firm posted ($0.06) EPS. The business’s revenue was up 49.5% compared to the same quarter last year. On average, equities research analysts anticipate that BioCryst Pharmaceuticals, Inc. will post -0.36 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Theresa Heggie sold 70,000 shares of the business’s stock in a transaction dated Wednesday, August 13th. The stock was sold at an average price of $8.51, for a total value of $595,700.00. Following the completion of the transaction, the director owned 65,352 shares of the company’s stock, valued at $556,145.52. The trade was a 51.72% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 5.10% of the stock is currently owned by company insiders.

BioCryst Pharmaceuticals Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.